SPY332.80-2.77 -0.83%
DIA277.19-0.95 -0.34%
IXIC10,782.82-185.53 -1.69%

Spectrum Pharmaceuticals shares are trading higher after the company announced on Monday results in HER2 Exon20 Insertion Mutations from Cohort 2 of the Poziotinib ZENITH20 trial met the pre-specified primary endpoint.

Benzinga · -